CURE Media Group

My oncology nurse has been making connections with her patients for more than 20 years. I’m forever grateful I was lucky to be her patient.

Twelve winners were selected from 113 submissions to have their artwork featured in its annual calendar contest.

View the full CURE® Educated Patient® Webinar: Testing and Treatment for Non-Small Cell Lung Cancer on demand.

View the full CURE® Educated Patient® Webinar: Meet the 2021 Lung Cancer Heroes® on demand.

View the full CURE Educated Patient Breast Cancer Summit Outside of Therapy Session on demand.

View the full CURE Educated Patient Breast Cancer Summit Novel Therapies Session on demand.

View the full CURE Educated Patient Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session on demand.

View the full CURE® Educated Patient® Webinar: Stomach Cancer 101 Series: Part III – Survivorship and Mental Health

The SAP program is a collaborative platform to showcase cutting-edge initiatives, research, and thought leadership.

Take-home messages from a discussion on the use of biomarker testing, and newer, novel-based strategies to treat patients with non-small cell lung cancer.

Preferences for rechallenging patients with non-small cell lung cancer with immunotherapy based on previous experiences in terms of treatment-related side effects.

Strategies that can help various health care professionals best mitigate or manage side effects associated with newer treatments in non-small cell lung cancer, such as immunotherapy.

The significance of shared decision-making between patients and lung oncologists when considering a novel-based therapy as treatment for non-small cell lung cancer.

Considerations for treating patients with non-small cell lung cancer with single-agent immunotherapy vs chemoimmunotherapy.

View the full CURE® Educated Patient® Webinar: Understanding Myeloproliferative Neoplasms (MPNs) and Treatment Options on demand.

Watch the entire Lung Cancer Heroes® presentation here!

Stephen Liu, MD, and Danielle Hicks clarify the importance of involving patients and caregivers in discussions about non-small cell lung cancer molecular testing.

Thought leaders give an overview on KRAS-mutated non-small cell lung cancer and the treatment options available.

View the full CURE Educated Patient Kidney Cancer Summit on demand.

Preferences for repeat biopsies upon progression in non-small cell lung cancer following frontline therapy with a targeted treatment approach.

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer.

Stephen Liu, MD, and Danielle Hicks illustrate how molecular testing impacts targeted therapy selection in non-small cell lung cancer.

Key opinion leaders explain how to discuss biomarker testing with non-small cell lung cancer patients, as well as the common questions they field.

The rationale for waiting on results of molecular testing prior to initiating treatment for patients with non-small cell lung cancer.

The difference between tissue and liquid biopsies used in non-small cell lung cancer, and what patients should know about their results and treatment decision-making.

Stephen Liu, MD, and Danielle Hicks describe the purpose and the importance of biomarker testing in non-small cell lung cancer.

Shared insight on novel treatments for non-small cell lung cancer and how patients should advocate for themselves and seek best available care.

Allison Collins shares her experience undergoing a break from therapy after she responded well to treatment for non-small cell lung cancer.

What patients need to know about molecular testing and treatment decisions in non-small cell lung cancer.

Reactions to low rates of molecular testing for patients with non-small cell lung cancer in community settings.